Stephen Parker Buys 84,033 Shares of Sareum Holdings plc (LON:SAR) Stock

Sareum Holdings plc (LON:SAR) insider Stephen Parker bought 84,033 shares of the firm’s stock in a transaction dated Wednesday, March 26th. The stock was purchased at an average cost of GBX 12 ($0.16) per share, with a total value of £10,083.96 ($13,051.98).

Sareum Stock Up 3.4 %

Shares of SAR stock opened at GBX 13.44 ($0.17) on Friday. The stock has a market cap of £16.79 million, a price-to-earnings ratio of -3.18 and a beta of -1.08. The business’s fifty day moving average is GBX 17.47 and its 200 day moving average is GBX 23.05. Sareum Holdings plc has a twelve month low of GBX 10.03 ($0.13) and a twelve month high of GBX 52.50 ($0.68).

Sareum (LON:SAR) last released its earnings results on Tuesday, March 25th. The company reported GBX (0.90) (($0.01)) earnings per share for the quarter. Equities research analysts expect that Sareum Holdings plc will post -3.8 earnings per share for the current fiscal year.

Sareum Company Profile

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.